Healthcare - Oncology
Companies developing cancer therapeutics, diagnostics, and precision oncology tools
Immunotherapy & Immuno-Oncology78
Targeted Therapy & Precision Oncology95
Cell & Gene Therapy for Cancer35
Radiopharmaceuticals & ADCs11
Cancer Diagnostics & Biomarkers28
| Ticker | Company | Sub-Theme | Mkt Cap▼ | Price | Chg% | Volume |
|---|---|---|---|---|---|---|
 LLY | Eli Lilly & Co. | Targeted Therapy & Precision Oncology | $1.0t | $1159.02 | +2.4% | 1.9M |
 JNJ | Johnson & Johnson | Immunotherapy & Immuno-Oncology | $0.5t | $231.90 | -0.4% | 2.5M |
 ABBV | ABBVIE INC. | Immunotherapy & Immuno-Oncology | $384.7b | $222.33 | -2.2% | 1.7M |
 MRK | Merck & Co., Inc. | Immunotherapy & Immuno-Oncology | $293.2b | $119.85 | -0.8% | 3.1M |
 AZN | AstraZeneca PLC | Immunotherapy & Immuno-Oncology | $287.9b | $183.68 | -1.2% | 1.0M |
 AMGN | Amgen Inc | Immunotherapy & Immuno-Oncology | $181.8b | $345.87 | -1.1% | 726.4K |
 GILD | Gilead Sciences Inc | Cell & Gene Therapy for Cancer | $166.9b | $127.69 | -1.1% | 2.2M |
 BMY | Bristol-Myers Squibb Co. | Immunotherapy & Immuno-Oncology | $116.8b | $56.28 | -1.7% | 4.6M |
 REGN | Regeneron Pharmaceuticals Inc | Immunotherapy & Immuno-Oncology | $64.5b | $617.68 | -2.8% | 235.2K |
 RVMD | Revolution Medicines, Inc. Common Stock | Targeted Therapy & Precision Oncology | $33.5b | $149.47 | +0.2% | 937.9K |
 NTRA | Natera, Inc. Common Stock | Cancer Diagnostics & Biomarkers | $32.0b | $214.98 | -0.2% | 335.2K |
 RPRX | Royalty Pharma plc Class A Ordinary Shares | Immunotherapy & Immuno-Oncology | $24.7b | $55.64 | -0.4% | 1.4M |
 INCY | Incyte Genomics Inc | Targeted Therapy & Precision Oncology | $19.3b | $101.05 | -1.3% | 983.8K |
 MRNA | Moderna, Inc. Common Stock | Immunotherapy & Immuno-Oncology | $18.7b | $47.88 | +0.9% | 1.6M |
 GH | Guardant Health, Inc. Common Stock | Cancer Diagnostics & Biomarkers | $17.2b | $127.25 | +1.3% | 566.9K |
 JAZZ | Jazz Pharmaceuticals, Inc. | Targeted Therapy & Precision Oncology | $14.8b | $235.03 | -1.5% | 464.4K |
 EXEL | Exelixis Inc | Targeted Therapy & Precision Oncology | $12.7b | $51.64 | -2.0% | 429.8K |
 NUVL | Nuvalent, Inc. Class A Common Stock | Targeted Therapy & Precision Oncology | $8.7b | $88.53 | -2.7% | 381.0K |
 HALO | Halozyme Therapeutics, Inc. | Targeted Therapy & Precision Oncology | $7.9b | $71.55 | +0.0% | 535.5K |
 IBRX | ImmunityBio, Inc. Common Stock | Immunotherapy & Immuno-Oncology | $7.9b | $7.14 | +3.2% | 5.4M |
 CORT | Corcept Therapeutics Inc. | Targeted Therapy & Precision Oncology | $7.5b | $74.85 | +3.1% | 244.6K |
 ACLX | Arcellx, Inc. Common Stock | Immunotherapy & Immuno-OncologyCell & Gene Therapy for Cancer | $6.7b | $115.06 | -0.0% | 16.1M |
 CELC | Celcuity Inc. Common Stock | Targeted Therapy & Precision Oncology | $6.5b | $89.02 | +0.8% | 466.0K |
 LNTH | Lantheus Holdings, Inc | Radiopharmaceuticals & ADCs | $6.5b | $101.22 | +0.2% | 173.8K |
 COGT | Cogent Biosciences, Inc. Common Stock | Targeted Therapy & Precision Oncology | $6.0b | $31.63 | +2.0% | 505.7K |
 CGON | CG Oncology, Inc. Common stock | Immunotherapy & Immuno-Oncology | $5.5b | $54.03 | +0.6% | 259.9K |
 CAI | Caris Life Sciences, Inc. Common Stock | Cancer Diagnostics & Biomarkers | $4.7b | $16.56 | +0.4% | 785.2K |
 BLLN | BillionToOne, Inc. Class A Common Stock | Cancer Diagnostics & Biomarkers | $4.6b | $97.88 | +0.7% | 350.7K |
 ERAS | Erasca, Inc. Common Stock | Targeted Therapy & Precision Oncology | $4.0b | $12.75 | +6.5% | 2.2M |
 VCYT | Veracyte, Inc. | Cancer Diagnostics & Biomarkers | $3.7b | $48.09 | -1.3% | 360.4K |
 RCUS | Arcus Biosciences, Inc. | Immunotherapy & Immuno-Oncology | $3.2b | $23.57 | +1.6% | 309.5K |
 TNGX | Tango Therapeutics, Inc. | Targeted Therapy & Precision Oncology | $3.2b | $28.89 | +42.9% | 12.7M |
 GRAL | GRAIL, Inc. Common Stock | Cancer Diagnostics & Biomarkers | $3.1b | $61.38 | +2.3% | 209.7K |
 RLAY | Relay Therapeutics, Inc. Common Stock | Targeted Therapy & Precision Oncology | $3.1b | $13.82 | +2.2% | 845.6K |
 IDYA | IDEAYA Biosciences, Inc. Common Stock | Targeted Therapy & Precision Oncology | $2.6b | $31.09 | +9.9% | 783.9K |
 ELVN | Enliven Therapeutics, Inc. Common Stock | Targeted Therapy & Precision Oncology | $2.5b | $34.34 | -1.1% | 257.8K |
 IMNM | Immunome, Inc. | Targeted Therapy & Precision OncologyRadiopharmaceuticals & ADCs | $2.5b | $18.48 | -0.5% | 258.4K |
 ADPT | Adaptive Biotechnologies Corporation Common Stock | Cancer Diagnostics & Biomarkers | $2.4b | $16.84 | -0.3% | 789.4K |
 DAWN | Day One Biopharmaceuticals, Inc. Common Stock | Targeted Therapy & Precision Oncology | $2.2b | $21.52 | -0.0% | 3.0M |
 NKTR | Nektar Therapeutics | Immunotherapy & Immuno-Oncology | $2.2b | $55.92 | -2.4% | 389.8K |
 TYRA | Tyra Biosciences, Inc. Common Stock | Targeted Therapy & Precision Oncology | $2.0b | $26.55 | -0.3% | 281.4K |
 NVCR | NovoCure Limited Ordinary Shares | Targeted Therapy & Precision Oncology | $2.0b | $17.52 | +2.1% | 362.0K |
 NTLA | Intellia Therapeutics, Inc | Cell & Gene Therapy for Cancer | $2.0b | $13.46 | -0.6% | 1.5M |
 ABCL | AbCellera Biologics Inc. Common Shares | Radiopharmaceuticals & ADCs | $1.9b | $5.38 | -4.4% | 2.4M |
 ZYME | Zymeworks Inc. | Targeted Therapy & Precision Oncology | $1.8b | $23.99 | -0.2% | 173.6K |
 NRIX | Nurix Therapeutics, Inc. Common stock | Targeted Therapy & Precision Oncology | $1.8b | $15.69 | +7.2% | 15.4M |
 IOVA | Iovance Biotherapeutics, Inc. Common Stock | Cell & Gene Therapy for CancerImmunotherapy & Immuno-Oncology | $1.8b | $4.12 | -2.7% | 4.7M |
 SNDX | Syndax Pharmaceuticals, Inc. | Immunotherapy & Immuno-Oncology | $1.7b | $16.96 | -2.2% | 750.9K |
 SLS | SELLAS Life Sciences Group, Inc. Common Stock | Immunotherapy & Immuno-Oncology | $1.7b | $8.14 | -1.0% | 3.3M |
 GLUE | Monte Rosa Therapeutics, Inc. Common Stock | Targeted Therapy & Precision Oncology | $1.7b | $16.84 | +2.9% | 1.1M |